8-K: CDT Equity Acquires 20% of Sarborg, Extends Key Consulting Deals

Sentiment:

Acquisition and Consulting Agreement Updates 24 February 2026 5:11 PM

📋All filings for Conduit Pharmaceuticals INC

CDT Equity Inc. announced the acquisition of a 20% stake in Sarborg Limited for common stock, pre-funded warrants, and deferred cash, alongside extensions of two significant consulting agreements.

Delay expectedThe exercise of the pre-funded warrants for the Sarborg acquisition is contingent on obtaining shareholder approval, which could delay the full issuance of the underlying common stock.The $8 million cash payment for the Sarborg acquisition is deferred until the company raises at least $20 million through an at-the-market facility, introducing a delay in the full consideration payment.

Capital raiseThe $8 million cash payment for the Sarborg acquisition is explicitly deferred until CDT Equity Inc. raises no less than $20 million through an at-the-market facility program, indicating a planned future capital raise.The issuance of pre-funded warrants, which are a form of future equity, implies a capital-raising activity, as the initial funding for these warrants was 'pre-funded' to the company.

Worse than expectedThe significant potential for dilution from the issuance of 598,006 common shares and pre-funded warrants for up to 109,978,918 shares for the Sarborg acquisition, relative to the 2,991,521 shares outstanding, is substantial.The additional issuance of 199,734 shares for NJS and 341,702 shares for Thesprogen further exacerbates dilution.The $8 million cash payment for Sarborg is deferred and contingent on a future $20 million capital raise, indicating potential cash constraints or a reliance on future financing that is not yet secured.

Summary

Acquired approximately 20% of Sarborg Limited (1,020 shares) on February 19, 2026, through a Securities Purchase Agreement.
Consideration for the Sarborg acquisition includes 598,006 shares of CDT Equity Inc. common stock and pre-funded warrants to purchase up to 109,978,918 shares of common stock, with a nominal exercise price of $0.0001 per share.
A deferred cash payment of $8 million to Sarborg is contingent on CDT Equity Inc. raising at least $20 million through an at-the-market facility program.
Extended the consulting agreement with NJS Foresight Bio-Advisory, LLC by 12 months, from December 29, 2026, to December 29, 2027, for an additional $150,000 retainer paid in 199,734 shares of common stock (valued at $0.751 per share).
Extended the consulting agreement with Thesprogen, PC by 12 months, from June 28, 2026, to June 28, 2027, for an additional $245,000 retainer paid in 341,702 shares of common stock (valued at $0.717 per share).
Previously issued 130,000 shares of common stock to Maxim Partners LLC as partial consideration for investment banking services.
All newly issued shares and warrants were unregistered, relying on exemptions from registration under the Securities Act of 1933.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution due to the substantial potential for shareholder dilution from the Sarborg acquisition and consulting extensions, coupled with a deferred cash payment contingent on a future capital raise, which introduces financial uncertainty.

Positives

Strategic acquisition of a 20% stake in Sarborg Limited, potentially expanding the company's asset portfolio and strategic reach.
The $8 million cash payment for the Sarborg acquisition is deferred, reducing immediate cash outflow and linking the payment to future capital raising success.
Extension of key consulting agreements with NJS Foresight Bio-Advisory, LLC and Thesprogen, PC ensures continuity of advisory, business development, and pre-clinical data optimization services.
The pre-funded warrants have a nominal exercise price of $0.0001 per share, which is a favorable structure for the holder.

Negatives

Significant potential for dilution from the issuance of 598,006 common shares and pre-funded warrants for up to 109,978,918 shares for the Sarborg acquisition, relative to the 2,991,521 shares outstanding prior to these transactions.
The additional issuance of 199,734 shares for NJS and 341,702 shares for Thesprogen further contributes to shareholder dilution.
The $8 million cash payment for Sarborg is deferred and contingent on a future $20 million capital raise, introducing uncertainty regarding the timing and success of this financing.
The exercise of pre-funded warrants is subject to shareholder approval if the issuance exceeds 19.99% of outstanding common stock, which could delay full exercise and introduce additional corporate governance hurdles.

Risks

Dilution Risk: The issuance of a large number of common shares and pre-funded warrants (up to 109,978,918 shares) for the Sarborg acquisition, along with shares for consulting services, poses a significant risk of dilution for existing shareholders.
Shareholder Approval Risk: The exercise of pre-funded warrants is contingent on obtaining shareholder approval for issuances exceeding 19.99% of outstanding common stock, which could delay or prevent full exercise.
Financing Contingency Risk: The $8 million cash consideration for Sarborg is deferred until the company raises at least $20 million through an at-the-market facility, introducing uncertainty regarding the timing and success of this financing.
Regulatory Compliance Risk: The company must file a resale registration statement within 60 days for the newly issued shares and warrant shares; failure to do so could impact the investors' ability to resell.
Market Price Volatility: The value of the stock-based consideration and the exercise of warrants are tied to the company's common stock price, which is subject to market fluctuations.
Beneficial Ownership Limitation: A 49.99% beneficial ownership limitation on warrant exercise could restrict a holder's ability to fully convert their warrants if they approach this threshold.

Future Outlook

The company plans to file a resale registration statement within 60 days for the shares and warrant shares issued in the Sarborg acquisition. The $8 million cash payment for Sarborg is contingent on a future capital raise of at least $20 million through an at-the-market facility. The extensions of consulting agreements indicate continued focus on advisory, business development, and pre-clinical data optimization through December 2027 and June 2027, respectively.

Management Comments

Andrew Regan, Chief Executive Officer of CDT Equity Inc., signed the Form 8-K.
James Bligh, Chief Financial Officer of CDT Equity Inc., signed the Securities Purchase Agreement and the Addendums to the Consulting Agreements.

Industry Context

StockSavvy.ai notes that the acquisition of a stake in Sarborg Limited, a Cayman Islands company, suggests CDT Equity Inc. is pursuing strategic expansion or diversification, potentially into new markets or technologies. The extensions of consulting agreements with NJS Foresight Bio-Advisory, LLC and Thesprogen, PC highlight a continued reliance on external expertise for business development, licensing, and pre-clinical data optimization, which is common for smaller biotech or equity firms seeking specialized knowledge without expanding internal teams. The use of equity and deferred cash for the acquisition, along with equity for consulting services, reflects a strategy to conserve cash while leveraging stock as a currency, a common practice in capital-intensive or early-stage industries.

Comparison to Industry Standards

The use of pre-funded warrants with a nominal exercise price is a common financing mechanism, particularly for companies seeking to raise capital while managing immediate dilution or providing attractive terms to investors.
Contingent cash payments, such as the $8 million for Sarborg tied to a future capital raise, are not uncommon in acquisitions, especially when the acquiring company aims to align payment with future funding events or operational milestones.
Issuing equity for consulting services is a standard practice for companies, especially those with limited cash flow, to compensate advisors and align their interests with the company's performance.
The 19.99% Nasdaq Share Cap requiring shareholder approval for further equity issuance is a standard Nasdaq listing rule (Rule 5635(d)) designed to protect existing shareholders from excessive dilution without their consent.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Shareholder Approval Requirement	Shareholder approval is required for the issuance of shares underlying the pre-funded warrants if the aggregate issuance exceeds 19.99% of the common stock or voting power outstanding on the date of the Purchase Agreement, in accordance with Nasdaq rules.	February 19, 2026	Ensures shareholder oversight on significant dilution events, potentially delaying full warrant exercise.
Beneficial Ownership Limitation	A 49.99% beneficial ownership limitation is imposed on the exercise of warrants, preventing any single holder (and their affiliates) from owning more than this percentage of outstanding common stock after exercise.	February 19, 2026	Limits concentration of ownership by warrant holders, potentially reducing control risk but also limiting large-scale investment.

Related Party Transactions

Andrew Regan, a director and CEO of CDT Equity Inc., is also a director of Sarborg Limited. He did not receive any consideration from the transaction.
Chele Farley, a director of CDT Equity Inc., is a less than 2% shareholder of Sarborg Limited and participated in the transaction, receiving 10,533 shares of Common Stock and pre-funded warrants for 1,940,804 shares. She received consideration proportionate to other investors.

Stakeholder Impact

Shareholders: Significant potential for dilution due to the issuance of a large number of common shares and warrants for the Sarborg acquisition and consulting services. The value of existing shares could be negatively impacted.
Warrant Holders (Sarborg Investors): Will receive common stock and pre-funded warrants, providing them with future equity upside, but subject to shareholder approval for full exercise and resale restrictions.
Sarborg Limited: Will receive CDT Equity Inc. stock, warrants, and a deferred $8 million cash payment, integrating it further with CDT Equity Inc.
Consultants (NJS and Thesprogen): Will continue to provide services and receive additional compensation in the form of CDT Equity Inc. common stock, aligning their interests with the company's performance.
Potential Future Investors: The need for a future $20 million capital raise could present an investment opportunity, but also indicates ongoing funding requirements.

Next Steps

Obtain requisite shareholder approval for the exercise of pre-funded warrants exceeding the 19.99% Nasdaq Share Cap.
Prepare and file a resale registration statement with the SEC for the Shares and Pre-Funded Warrant Shares within 60 days of the closing date (by April 20, 2026).
Pursue an at-the-market facility program to raise at least $20 million to trigger the $8 million deferred cash payment for Sarborg.
NJS Foresight Bio-Advisory, LLC to continue providing advisory and business development services until December 29, 2027.
Thesprogen, PC to continue evaluating pre-clinical data and devising strategies until June 28, 2027.

Key Dates

Date	Description
2025-12-28	Original Consulting Agreement with Thesprogen, PC effective date.
2025-12-29	Original Consulting Agreement with NJS Foresight Bio-Advisory, LLC effective date.
2026-01-02	Date of previous 8-K filing regarding NJS and Thesprogen agreements.
2026-02-18	Date of Securities Purchase Agreement for Sarborg acquisition; also the date for outstanding common stock count (2,991,521 shares).
2026-02-19	Issue Date of Pre-Funded Common Stock Purchase Warrant; Date of earliest event reported in 8-K; Closing Date for Sarborg acquisition.
2026-02-20	Trading day prior to NJS Addendum Effective Date, used for NJS Shares valuation ($0.751 per share).
2026-02-23	NJS Addendum Effective Date; Trading day prior to Thesprogen Addendum Effective Date, used for Thesprogen Shares valuation ($0.717 per share).
2026-02-24	Thesprogen Addendum Effective Date; Date of 8-K filing and signature by Andrew Regan.
2026-04-20	Approximate deadline for filing resale registration statement (60 days from Feb 19, 2026).
2026-06-28	Original termination date of Thesprogen Agreement.
2026-12-29	Original termination date of NJS Agreement.
2027-06-28	New termination date of Thesprogen Agreement after extension.
2027-12-29	New termination date of NJS Agreement after extension.

Recommendation

hold

The strategic acquisition of a stake in Sarborg and the extension of key consulting agreements suggest ongoing business development and a commitment to asset optimization. However, the substantial potential for dilution from the equity issuances, particularly the large number of warrant shares, and the contingency of the $8 million cash payment on a future capital raise introduce significant uncertainty and risk. Investors should hold to monitor the execution of the Sarborg integration, the success of the planned capital raise, and the impact of dilution on share value before making further investment decisions.

Keywords

CDT Equity Inc., Sarborg Limited, Acquisition, Pre-Funded Warrants, Common Stock, SEC Filing, 8-K, Consulting Agreement, NJS Foresight Bio-Advisory, Thesprogen PC, Equity Issuance, Dilution, Nasdaq, Capital Raise, Investment Banking Services

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.